StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Next report date, year-over-year trend, and recent quarter history.
5-factor analysis: Valuation, Growth, Profitability, Momentum, Financial Health.
Factor scoring needs Finnhub-supplied fundamentals — Finnhub returned no fundamental metrics for this ticker. Common for ETFs, foreign filers without US listing depth, recent IPOs, and thinly-traded OTC names.
6-factor scoring with sector-relative rank. Updated daily.
Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-11 | $0.23 | $0.25 | +10.09% | 5.1M |
| 05-12 | $0.24 | $0.24 | -0.41% | 2.2M |
| 05-13 | $0.23 | $0.23 | -2.13% | 2.2M |
| 05-14 | $0.24 | $0.23 | -1.10% | 3.0M |
| 05-15 | $0.23 | $0.23 | -2.81% | 2.7M |
These are published opinions from external sell-side analysts — not Stonvex recommendations. Ratings may change without notice, may conflict with each other, and may be wrong. Not investment advice.
Consensus aggregated from publicly disclosed sell-side analyst ratings. Stonvex is not a registered investment advisor and does not endorse any of the ratings shown. Past analyst ratings do not predict future price movements.
| Metric | Annual 2025 2025-09-30 | Q2 2025 2025-06-30 |
|---|---|---|
Revenue | $1.41M | $1.51M |
Operating Income | $-67.06M | $-49.75M |
Net Income | $-62.42M | $-49.13M |
EPS (Diluted) | $-1.79 | $-1.60 |
Total Assets | $18.58M | $22.39M |
Total Liabilities | $50.77M | $59.58M |
Cash & Equivalents | $8.08M | $8.90M |
Free Cash Flow OCF − CapEx | Not available | Not available |
Shares Outstanding | 53.89M | 43.48M |
Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA, which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.